Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Spending Continues To Lag Overall Health Growth; New Drugs Have Positive Impact in 2011 Data

This article was originally published in RPM Report

Executive Summary

Prescription drug spending modestly increased in 2011 but continues to lag historically slow rates of overall health spending growth. But it could have been worse: government actuaries cite spending on new brands as driving what growth there is.

You may also be interested in...

Drug Spending Expected To Rise By $200 Bil. In 2022 Compared To Pre-ACA Levels

Implementation of the Affordable Care Act in 2014 will help significantly increase growth for pharma. The increase won’t be as big as it might have been, thanks to the Supreme Court ruling allowing states to opt out of Medicaid expansion, but it should still be a significant acceleration.

Part D’s Standard Deductible, Copays To Drop In 2014

With dropping drug expenses in Part D, CMS’ annual call letter for Part D drug plans proposes reducing beneficiary expenses for the standard plan in 2014, the first drop since the program began.

Pharma Projected to Have ACA to Thank for Growth - Assuming it Remains As-Is

The Centers for Medicare and Medicaid’s Office of the Actuary projects that aggregate health care spending will grow modestly - then spike in 2014. That’s due to coverage expansions in the Affordable Care Act, and pharma stands to get among the biggest gains. The June report release means industry would have at least a couple weeks to enjoy the projections before they potentially no longer apply.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts